|
US5366738A
(en)
*
|
1982-07-29 |
1994-11-22 |
Merck & Co., Inc. |
Controlled release drug dispersion delivery device
|
|
US5250082A
(en)
*
|
1991-01-04 |
1993-10-05 |
Development Center For Biotechnology |
Encapsulated structure for plant initiate material
|
|
US5543154A
(en)
*
|
1991-12-27 |
1996-08-06 |
Merck & Co., Inc. |
Controlled release nifedipine delivery device
|
|
TW235239B
(de)
*
|
1992-11-20 |
1994-12-01 |
Pfizer |
|
|
ATE537858T1
(de)
|
1993-07-19 |
2012-01-15 |
Angiotech Pharm Inc |
Anti-angiogene mittel und verfahren zu deren verwendung
|
|
US5500227A
(en)
*
|
1993-11-23 |
1996-03-19 |
Euro-Celtique, S.A. |
Immediate release tablet cores of insoluble drugs having sustained-release coating
|
|
US6210714B1
(en)
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
|
US5523095A
(en)
*
|
1993-12-15 |
1996-06-04 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
|
|
US5536505A
(en)
*
|
1993-12-15 |
1996-07-16 |
Eastman Chemical Company |
Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
|
|
US5554147A
(en)
*
|
1994-02-01 |
1996-09-10 |
Caphco, Inc. |
Compositions and devices for controlled release of active ingredients
|
|
US5788687A
(en)
|
1994-02-01 |
1998-08-04 |
Caphco, Inc |
Compositions and devices for controlled release of active ingredients
|
|
US5419917A
(en)
*
|
1994-02-14 |
1995-05-30 |
Andrx Pharmaceuticals, Inc. |
Controlled release hydrogel formulation
|
|
US5458887A
(en)
*
|
1994-03-02 |
1995-10-17 |
Andrx Pharmaceuticals, Inc. |
Controlled release tablet formulation
|
|
AT403988B
(de)
*
|
1994-05-18 |
1998-07-27 |
Lannacher Heilmittel |
Festes orales retardpräparat
|
|
EP0807433A4
(de)
*
|
1994-12-27 |
2005-12-28 |
Akzo Nobel Nv |
Zubereitung mit verzögerter freisetzung
|
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
|
US5651979A
(en)
*
|
1995-03-30 |
1997-07-29 |
Gel Sciences, Inc. |
Apparatus and method for delivering a biologically active compound into a biological environment
|
|
WO1998017260A1
(en)
*
|
1995-06-07 |
1998-04-30 |
Medlogic Global Corporation |
Chemo-mechanical expansion delivery system
|
|
US6858589B2
(en)
|
1996-01-25 |
2005-02-22 |
Pharmacy And Therapeutic Advisory Consultancy Pty Ltd |
Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
|
|
WO1997049392A1
(en)
*
|
1996-06-24 |
1997-12-31 |
Merck & Co., Inc. |
A composition of enalapril and losartan
|
|
WO1998006692A1
(en)
*
|
1996-08-12 |
1998-02-19 |
Celgene Corporation |
Novel immunotherapeutic agents and their use in the reduction of cytokine levels
|
|
JP4863534B2
(ja)
*
|
1996-10-25 |
2012-01-25 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
可溶形態浸透用量送達システム
|
|
US6531154B1
(en)
*
|
1997-06-10 |
2003-03-11 |
Brown University Research Foundation |
Modulated release from biocompatible polymers
|
|
US6617488B1
(en)
*
|
1997-10-14 |
2003-09-09 |
Indicator Technologies, Inc. |
Method and apparatus for indicating the conditions in an absorbent article
|
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
|
US6090411A
(en)
*
|
1998-03-09 |
2000-07-18 |
Temple University |
Monolithic tablet for controlled drug release
|
|
US6099859A
(en)
*
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
|
CN1312717A
(zh)
*
|
1998-06-15 |
2001-09-12 |
塞普拉科有限公司 |
光学纯度(+)—降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
|
|
NZ535055A
(en)
|
1998-06-15 |
2006-04-28 |
Sepracor Inc |
Use of optically pure (-) norcisapride in the treatment of apnea, and other disorders
|
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
US6974838B2
(en)
*
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6099862A
(en)
*
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
|
EP1117384A1
(de)
*
|
1998-10-01 |
2001-07-25 |
Elan Pharma International Limited |
Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
|
|
WO2000025757A1
(en)
*
|
1998-10-29 |
2000-05-11 |
Merck & Co., Inc. |
Sustained release delivery of highly water-soluble compounds
|
|
US6342533B1
(en)
|
1998-12-01 |
2002-01-29 |
Sepracor, Inc. |
Derivatives of (−)-venlafaxine and methods of preparing and using the same
|
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
|
EP1181015A2
(de)
|
1999-03-01 |
2002-02-27 |
Sepracor Inc. |
Verfahren zur behandlung von apnoe und apnoe-erkrankungen mit optisch reinem r(+)ondansetron
|
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
|
US6353005B1
(en)
|
1999-03-02 |
2002-03-05 |
Sepracor, Inc. |
Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
|
|
US6362202B1
(en)
|
1999-03-02 |
2002-03-26 |
Sepracor Inc. |
Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
|
|
US20040121014A1
(en)
*
|
1999-03-22 |
2004-06-24 |
Control Delivery Systems, Inc. |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
|
US6217895B1
(en)
|
1999-03-22 |
2001-04-17 |
Control Delivery Systems |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
|
US6410052B1
(en)
|
1999-03-30 |
2002-06-25 |
Purdue Research Foundation |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
|
|
US6428818B1
(en)
|
1999-03-30 |
2002-08-06 |
Purdue Research Foundation |
Tea catechin formulations and processes for making same
|
|
EP1165487A1
(de)
*
|
1999-04-06 |
2002-01-02 |
Sepracor Inc. |
Venlafaxinderivate; ihre herstellung und ihre verwendung
|
|
US6951873B1
(en)
|
1999-04-27 |
2005-10-04 |
Pfizer Inc. |
Methods for treating age-related behavioral disorders in companion animals
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
CA2383785C
(en)
|
1999-09-03 |
2009-02-17 |
Eli Lilly And Company |
Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
|
|
JP2003514524A
(ja)
|
1999-11-18 |
2003-04-22 |
コルバス・インターナショナル・インコーポレイテッド |
エントセリアーゼをコードしている核酸、エンドセリアーゼおよびその使用
|
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
CA2395231C
(en)
|
1999-12-23 |
2006-08-15 |
Pfizer Products Inc. |
Hydrogel-driven layered drug dosage form
|
|
EP1242055B1
(de)
*
|
1999-12-23 |
2008-04-23 |
Pfizer Products Inc. |
Hydrogel-gesteuerte dosierungsform
|
|
US7700341B2
(en)
*
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
|
JP2003528918A
(ja)
*
|
2000-03-31 |
2003-09-30 |
セルジーン コーポレイション |
シクロオキシゲナーゼ−２活性の阻害
|
|
US6375972B1
(en)
|
2000-04-26 |
2002-04-23 |
Control Delivery Systems, Inc. |
Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
|
|
US7259152B2
(en)
|
2000-06-07 |
2007-08-21 |
Alfa Wasserman, Inc. |
Methods and compositions using sulodexide for the treatment of diabetic nephropathy
|
|
US20030086972A1
(en)
*
|
2000-08-09 |
2003-05-08 |
Appel Leah E. |
Hydrogel-driven drug dosage form
|
|
AU8130401A
(en)
|
2000-08-15 |
2002-02-25 |
Surmodics Inc |
Medicament incorporation matrix
|
|
US20060034922A1
(en)
*
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
|
US6790459B1
(en)
|
2000-11-03 |
2004-09-14 |
Andrx Labs, Llc |
Methods for treating diabetes via administration of controlled release metformin
|
|
US20070208087A1
(en)
|
2001-11-02 |
2007-09-06 |
Sanders Virginia J |
Compounds, compositions and methods for the treatment of inflammatory diseases
|
|
US6866866B1
(en)
*
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
|
EP1353672B1
(de)
*
|
2000-11-30 |
2007-10-03 |
The Children's Medical Center Corporation |
Synthese von 4-aminothalidomid enantiomeren
|
|
US20030167524A1
(en)
*
|
2000-12-19 |
2003-09-04 |
Rooijen Gijs Van |
Methods for the production of multimeric protein complexes, and related compositions
|
|
PL362687A1
(en)
|
2001-01-12 |
2004-11-02 |
Sun Pharmaceutical Industries Limited |
Spaced drug delivery system
|
|
JP4220243B2
(ja)
*
|
2001-02-12 |
2009-02-04 |
ワイス |
Ｏ−デスメチル−ベンラファキシンの新規コハク酸塩
|
|
AU2002305052A1
(en)
|
2001-03-13 |
2002-09-24 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
|
JP2004535166A
(ja)
|
2001-03-22 |
2004-11-25 |
デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー |
セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
|
|
KR20030096292A
(ko)
|
2001-03-27 |
2003-12-24 |
덴드레온 샌 디에고 엘엘씨 |
트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
|
US6610887B2
(en)
|
2001-04-13 |
2003-08-26 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
EP1539942A4
(de)
|
2001-05-14 |
2005-10-19 |
Dendreon Corp |
Eine transmembran-serinprotease 10 codierende nukleinsäuremoleküle, die codierten polypeptide und darauf beruhende verfahren
|
|
AU2002346065A1
(en)
*
|
2001-07-05 |
2003-01-21 |
Marantech Holding, Llc |
Methods of using electron active compounds for managing conditions afflicting mammals
|
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
|
JP2005525299A
(ja)
*
|
2001-09-14 |
2005-08-25 |
スコラー インコーポレイテッド |
アミノ酸調節性の長期放出投薬形態
|
|
DE60223695T2
(de)
*
|
2001-09-14 |
2008-10-30 |
Scolr, Inc., Redmond |
Aminosäure-modulierte dosierform mit verlängerter freisetzung
|
|
US20070098784A1
(en)
|
2001-09-28 |
2007-05-03 |
Nutraceutix, Inc. |
Delivery system for biological component
|
|
US20030118649A1
(en)
*
|
2001-10-04 |
2003-06-26 |
Jinming Gao |
Drug delivery devices and methods
|
|
US20030134794A1
(en)
*
|
2001-11-20 |
2003-07-17 |
Madison Edwin L. |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
|
WO2003049673A2
(en)
|
2001-12-05 |
2003-06-19 |
Baylor College Of Medicine |
Methods and compositions for control of bone formation via modulation of sympathetic tone
|
|
US20030181416A1
(en)
*
|
2002-01-10 |
2003-09-25 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
|
US20040009953A1
(en)
*
|
2002-01-10 |
2004-01-15 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
|
EP1472225B1
(de)
|
2002-02-01 |
2010-04-28 |
Euro-Celtique S.A. |
2-piperazinpyridine für die schmerzbehandlung
|
|
EP1474144B1
(de)
|
2002-02-01 |
2008-08-06 |
Pfizer Products Inc. |
Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
|
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
|
WO2003101392A2
(en)
*
|
2002-05-31 |
2003-12-11 |
Transform Pharmaceuticals, Inc. |
Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
|
|
US7446107B2
(en)
*
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
|
EP1494998A2
(de)
|
2002-03-01 |
2005-01-12 |
University Of South Florida |
Mehrkomponenten festphasen enthaltend wenigstens einen pharmazeutischen wirkstoff
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US20030224051A1
(en)
*
|
2002-05-31 |
2003-12-04 |
Fink Tracy A. |
Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
|
|
ES2320435T3
(es)
*
|
2002-04-29 |
2009-05-22 |
Alza Corporation |
Metodo y formas de dosificacion para la administracion controlada de oxicodona.
|
|
US7205413B2
(en)
*
|
2002-05-03 |
2007-04-17 |
Transform Pharmaceuticals, Inc. |
Solvates and polymorphs of ritonavir and methods of making and using the same
|
|
US8871241B2
(en)
*
|
2002-05-07 |
2014-10-28 |
Psivida Us, Inc. |
Injectable sustained release delivery devices
|
|
CN1668296A
(zh)
*
|
2002-05-17 |
2005-09-14 |
细胞基因公司 |
使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
|
SI1505973T1
(sl)
|
2002-05-17 |
2010-06-30 |
Celgene Corp |
Kombinacija za zdravljenje multiplega mieloma
|
|
AU2003241537A1
(en)
*
|
2002-05-23 |
2003-12-12 |
Andrx Corporation |
Biguanide formulations
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
US8829198B2
(en)
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
|
US6995168B2
(en)
*
|
2002-05-31 |
2006-02-07 |
Euro-Celtique S.A. |
Triazaspiro compounds useful for treating or preventing pain
|
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
ES2473581T3
(es)
*
|
2002-05-31 |
2014-07-07 |
Proteotech Inc. |
Compuestos, composiciones y métodos para el tratamiento de amiloidosis y sinucleinopat�as tales como la enfermedad de Alzheimer, la diabetes de tipo 2 y la enfermedad de Parkinson
|
|
IL165383A0
(en)
*
|
2002-06-21 |
2006-01-15 |
Transform Pharmaceuticals Inc |
Pharmaceutical compositions with improved dissolution
|
|
CA2493458A1
(en)
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
|
|
EP1543010B1
(de)
|
2002-09-25 |
2007-04-25 |
Euro-Celtique S.A. |
N-substituierte hydromorphone und ihre anwendung
|
|
WO2004028463A2
(en)
*
|
2002-09-27 |
2004-04-08 |
Bioenvision, Inc. |
Methods and compositions for the treatment of lupus using clofarabine
|
|
EP1549141A4
(de)
*
|
2002-09-27 |
2008-06-25 |
Bioenvision Inc |
Verfahren und zusammensetzungen für die behandlung von autoimmunerkrankungen unter verwendung von clofarabin
|
|
JP2006507357A
(ja)
*
|
2002-10-11 |
2006-03-02 |
プロテオテック・インコーポレイテッド |
プロシアニジンｂ２の単離、精製および合成ならびにその使用
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
BR0315316A
(pt)
*
|
2002-10-15 |
2005-08-16 |
Celgene Corp |
Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
EP1900369A1
(de)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
|
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
KR100923173B1
(ko)
|
2002-11-06 |
2009-10-22 |
셀진 코포레이션 |
암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨억제 약물의 사용 방법 및 그 조성물
|
|
MXPA05004777A
(es)
*
|
2002-11-06 |
2005-07-22 |
Celgene Corp |
Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
|
|
AU2003294311B8
(en)
*
|
2002-11-18 |
2008-06-05 |
Celgene Corporation |
Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
MXPA05005161A
(es)
*
|
2002-11-18 |
2005-07-22 |
Celgene Corp |
Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
|
|
CA2508948A1
(en)
*
|
2002-12-16 |
2004-07-15 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
|
US8183290B2
(en)
*
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
|
EP2339328A3
(de)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
|
|
JP4923182B2
(ja)
|
2003-02-28 |
2012-04-25 |
マクニール−ピーピーシー・インコーポレーテツド |
セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
|
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
|
ATE448323T1
(de)
*
|
2003-03-05 |
2009-11-15 |
Halozyme Inc |
Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
WO2004108067A2
(en)
*
|
2003-04-03 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
Programmed drug delivery system
|
|
WO2004091278A2
(en)
*
|
2003-04-11 |
2004-10-28 |
Transform Pharmaceuticals, Inc. |
Gabapentin compositions
|
|
WO2004091502A2
(en)
|
2003-04-11 |
2004-10-28 |
Ptc Therapeutics, Inc. |
1,2,4-oxadiazole benzoic acid compounds
|
|
AU2004265226A1
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
|
US7186863B2
(en)
*
|
2003-05-23 |
2007-03-06 |
Transform Pharmaceuticals, Inc. |
Sertraline compositions
|
|
US20090227647A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Thomas Lake |
Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
|
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
|
US7438903B2
(en)
*
|
2003-06-06 |
2008-10-21 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
|
TWI287010B
(en)
*
|
2003-06-12 |
2007-09-21 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
|
ATE423111T1
(de)
*
|
2003-07-03 |
2009-03-15 |
Euro Celtique Sa |
2-pyridin alkyne derivaten und ihre verwendung für die schmerzbehandlung
|
|
WO2005004882A1
(en)
*
|
2003-07-09 |
2005-01-20 |
Monash University |
Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
|
|
BRPI0412805A
(pt)
*
|
2003-07-23 |
2006-09-26 |
Synta Pharmaceuticals Corp |
método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio
|
|
EP1867644B1
(de)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
|
|
CN101914088A
(zh)
*
|
2003-07-24 |
2010-12-15 |
尤罗塞尔蒂克股份有限公司 |
哌啶化合物和含有它们的药物组合物
|
|
BRPI0412248B1
(pt)
*
|
2003-07-24 |
2018-12-26 |
Euro Celtique Sa |
agentes terapêuticos úteis para tratar dor, composição farmacêutica, uso, kit e processo para preparação da dita composição
|
|
PL1942106T3
(pl)
*
|
2003-08-01 |
2012-02-29 |
Euro Celtique Sa |
Środki lecznicze użyteczne do leczenia bólu
|
|
MXPA06002443A
(es)
*
|
2003-09-03 |
2006-08-31 |
Agi Therapeutics Ltd |
Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
|
|
UA83504C2
(en)
*
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
CN1856489A
(zh)
*
|
2003-09-22 |
2006-11-01 |
欧洲凯尔特公司 |
用于治疗疼痛的苯甲酰胺化合物
|
|
CN1863790A
(zh)
*
|
2003-09-22 |
2006-11-15 |
欧洲凯尔特公司 |
用于治疗疼痛的治疗药
|
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
|
CA2545128C
(en)
*
|
2003-11-06 |
2010-01-12 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
|
US7387793B2
(en)
|
2003-11-14 |
2008-06-17 |
Eurand, Inc. |
Modified release dosage forms of skeletal muscle relaxants
|
|
US7470435B2
(en)
*
|
2003-11-17 |
2008-12-30 |
Andrx Pharmaceuticals, Llc |
Extended release venlafaxine formulation
|
|
AU2004293443A1
(en)
|
2003-11-19 |
2005-06-09 |
Signal Pharmaceuticals, Llc. |
Indazole Compounds and methods of use thereof as protein kinase inhibitors
|
|
US7829552B2
(en)
|
2003-11-19 |
2010-11-09 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyromimetics
|
|
PL1727801T3
(pl)
*
|
2003-12-30 |
2009-08-31 |
Euro Celtique Sa |
Piperazyny użyteczne do leczenia bólu
|
|
US20060018911A1
(en)
*
|
2004-01-12 |
2006-01-26 |
Dana Ault-Riche |
Design of therapeutics and therapeutics
|
|
EP2292213A1
(de)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Armodafinil Polymorph enthaltende Zusammensetzungen
|
|
US20060003001A1
(en)
*
|
2004-02-11 |
2006-01-05 |
John Devane |
Chronotherapeutic compositions and methods of their use
|
|
CA2555811A1
(en)
|
2004-02-18 |
2005-08-25 |
Gpc Biotech Ag |
Methods for treating resistant or refractory tumors
|
|
KR101224262B1
(ko)
|
2004-03-22 |
2013-01-21 |
셀진 코포레이션 |
면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
|
|
WO2005092065A2
(en)
*
|
2004-03-25 |
2005-10-06 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
|
AU2004319758A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
CA2563207A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
|
KR20070007945A
(ko)
*
|
2004-04-23 |
2007-01-16 |
셀진 코포레이션 |
폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
|
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
|
US7803366B2
(en)
*
|
2004-05-07 |
2010-09-28 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
|
JP2008506366A
(ja)
*
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
|
WO2005117585A1
(en)
|
2004-05-28 |
2005-12-15 |
Transform Pharmaceuticals, Inc. |
Mixed co-crystals and pharmaceutical compositions comprising the same
|
|
US20080138282A1
(en)
*
|
2004-06-03 |
2008-06-12 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled Arylsulfonyl Compounds and Uses Thereof
|
|
JP5017103B2
(ja)
*
|
2004-06-17 |
2012-09-05 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
薬剤共結晶組成物および関連した使用方法
|
|
WO2006012536A2
(en)
|
2004-07-22 |
2006-02-02 |
Ritter Andrew J |
Methods and compositions for treating lactose intolerance
|
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
|
EP1786414A4
(de)
*
|
2004-08-06 |
2008-04-09 |
Transform Pharmaceuticals Inc |
Neue pharmazeutische statin-zusammensetzungen und relevante behandlungsverfahren
|
|
JP2008516890A
(ja)
*
|
2004-08-06 |
2008-05-22 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なフェノフィブラート製剤および関連治療方法
|
|
NZ554545A
(en)
|
2004-09-17 |
2010-10-29 |
Whitehead Inst Of Biomedical R |
Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
|
|
US7709518B2
(en)
*
|
2004-09-21 |
2010-05-04 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
|
MX2007005040A
(es)
*
|
2004-10-28 |
2007-06-19 |
Celgene Corp |
Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central.
|
|
WO2006053184A2
(en)
*
|
2004-11-10 |
2006-05-18 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating or preventing a vascular disease
|
|
WO2006055760A1
(en)
|
2004-11-18 |
2006-05-26 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
|
EP1831235B1
(de)
*
|
2004-12-16 |
2013-02-20 |
The Regents of The University of California |
Arzneimittel für die lungen
|
|
CA2589529C
(en)
|
2004-12-17 |
2013-09-10 |
Anadys Pharmaceuticals, Inc. |
3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof
|
|
EP2096107A1
(de)
|
2004-12-23 |
2009-09-02 |
GPC Biotech AG |
Derivate von Quadratsäure mit Wirkung gegen Proliferation
|
|
WO2006073779A1
(en)
*
|
2004-12-30 |
2006-07-13 |
Transform Phamaceuticals, Inc. |
Novel omeprazole forms and related methods
|
|
NZ556546A
(en)
|
2005-01-07 |
2011-02-25 |
Synta Pharmaceuticals Corp |
Compounds for inflammation and immune-related uses
|
|
CA2595855C
(en)
*
|
2005-01-25 |
2017-07-04 |
Synta Pharmaceuticals Corp. |
Pyrazine compounds for inflammation and immune-related uses
|
|
EP1866319B1
(de)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
|
WO2006119365A2
(en)
|
2005-05-02 |
2006-11-09 |
Cold Spring Harbor Laboratory |
Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
|
|
US20070087406A1
(en)
*
|
2005-05-04 |
2007-04-19 |
Pei Jin |
Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
|
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
|
US20070054868A1
(en)
*
|
2005-06-20 |
2007-03-08 |
The Trustees Of Columbia University In The City Of New York |
Synergistic polyphenol compounds, compositions thereof, and uses thereof
|
|
WO2007005961A2
(en)
*
|
2005-07-06 |
2007-01-11 |
Sepracor Inc. |
Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
|
|
US8221792B2
(en)
*
|
2005-07-07 |
2012-07-17 |
Farnam Companies, Inc. |
Sustained release pharmaceutical compositions for highly water soluble drugs
|
|
WO2007013929A1
(en)
|
2005-07-22 |
2007-02-01 |
Amgen Inc. |
Aniline sulfonamide derivatives and their uses
|
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
UA91560C2
(ru)
|
2005-08-31 |
2010-08-10 |
Селджин Корпорэйшн |
Соединения ряда изоиндолимидов, их композиция и применение
|
|
CA2620594C
(en)
*
|
2005-09-01 |
2012-08-21 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition having improved disintegratability
|
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
|
WO2008051197A2
(en)
*
|
2005-09-20 |
2008-05-02 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP1960382A1
(de)
|
2005-11-03 |
2008-08-27 |
ChemBridge Research Laboratories, Inc. |
Heterocyclische verbindungen als tyrosinkinasemodulatoren
|
|
US20070104788A1
(en)
|
2005-11-10 |
2007-05-10 |
Seamus Mulligan |
Once-daily administration of central nervous system drugs
|
|
WO2007058776A2
(en)
*
|
2005-11-10 |
2007-05-24 |
Receptor Biologix, Inc. |
Hepatocyte growth factor intron fusion proteins
|
|
UA91250C2
(en)
|
2005-11-21 |
2010-07-12 |
Пердью Фарма Л.П. |
4-oxadiazolyl-piperidine compounds and use thereof
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
CA2841386A1
(en)
*
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
|
EP1983980A4
(de)
*
|
2006-01-25 |
2010-05-05 |
Synta Pharmaceuticals Corp |
Thiazol- und thiadiazol-verbindungen für verwendungen in verbindung mit entzündung und immunität
|
|
TW200806290A
(en)
|
2006-01-25 |
2008-02-01 |
Synta Pharmaceuticals Corp |
Substituted biaryl compounds for inflammation and immune-related uses
|
|
JP2009524683A
(ja)
|
2006-01-25 |
2009-07-02 |
シンタ ファーマシューティカルズ コーポレーション |
炎症および免疫関連用途のためのビニル−フェニル誘導体
|
|
ES2403368T3
(es)
*
|
2006-01-31 |
2013-05-17 |
Synta Pharmaceuticals Corporation |
Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados
|
|
US7518017B2
(en)
|
2006-02-17 |
2009-04-14 |
Idexx Laboratories |
Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
|
|
MX2008011844A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Formulaciones de sitaxsentano de sodio.
|
|
CA2646438A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
|
DK2383271T3
(da)
*
|
2006-03-13 |
2013-10-07 |
Kyorin Seiyaku Kk |
Aminoquinoloner som GSK-3-inhibitorer
|
|
WO2007126841A2
(en)
*
|
2006-03-29 |
2007-11-08 |
Foldrx Pharmaceuticals, Inc. |
Inhibition of alpha-synuclein toxicity
|
|
DE602007008237D1
(de)
*
|
2006-06-08 |
2010-09-16 |
Amgen Inc |
Benzamidderivate und assoziierte verwendungen
|
|
TW200808695A
(en)
*
|
2006-06-08 |
2008-02-16 |
Amgen Inc |
Benzamide derivatives and uses related thereto
|
|
KR20090031897A
(ko)
*
|
2006-06-12 |
2009-03-30 |
리셉터 바이오로직스 인크 |
전-세포 표면 수용체-특이적 치료제
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
EP2038286B1
(de)
|
2006-06-22 |
2017-03-08 |
Anadys Pharmaceuticals, Inc. |
Pyrro[1,2-b]pyridazinon-verbindungen
|
|
TWI418561B
(zh)
|
2006-06-22 |
2013-12-11 |
Anadys Pharmaceuticals Inc |
５-胺基-３-（３’-去氧-β-Ｄ-核糖呋喃糖基（ｒｉｂｏｆｕｒａｎｏｓｙｌ））-噻唑并〔４，５-ｄ〕嘧啶-２，７-二酮之前藥
|
|
ES2579437T3
(es)
|
2006-07-05 |
2016-08-11 |
Catalyst Biosciences, Inc. |
Procedimientos de cribado de proteasas y proteasas identificadas por los mismos
|
|
EP2043603A4
(de)
|
2006-07-11 |
2010-10-27 |
Arubor Corp |
Prävention und therapie von rhinosinusitis mit proinflammatorischen zytokinhemmern
|
|
JP5225991B2
(ja)
|
2006-07-18 |
2013-07-03 |
アナディス ファーマシューティカルズ インク |
チアゾロ［４，５−ｄ］ピリミジンのカーボネート及びカルバメートプロドラッグ
|
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
EP2069021A2
(de)
*
|
2006-08-04 |
2009-06-17 |
AGI Therapeutics Research Limited |
Verfahren zur behandlung mindestens eines leidens mit mt1-rezeptor, 5ht2b-rezeptor- und l-calciumkanal-aktivität
|
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
|
CL2007002513A1
(es)
|
2006-08-30 |
2008-04-04 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
DK2066662T3
(da)
|
2006-09-21 |
2013-01-07 |
Kyorin Seiyaku Kk |
Serinhydrolaseinhibitorer
|
|
PL2428513T3
(pl)
|
2006-09-26 |
2017-10-31 |
Celgene Corp |
Pochodne 5-podstawionego chinazolinonu jako środki przeciwnowotworowe
|
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
|
US8653066B2
(en)
|
2006-10-09 |
2014-02-18 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
|
EP1914234A1
(de)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidinen und ihre Verwendung als kinase Inhibitoren
|
|
ES2402907T3
(es)
|
2006-10-19 |
2013-05-10 |
Genzyme Corporation |
Roscovitina para el tratamiento de ciertas enfermedades quísticas
|
|
CA2666149A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
|
AU2007322116B2
(en)
|
2006-11-13 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Cyclohexenyl-aryl compounds for inflammation and immune-related uses
|
|
US8808702B2
(en)
|
2006-12-13 |
2014-08-19 |
Temple University-Of The Commonwealth System Of Higher Education |
Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
|
|
CN101611008A
(zh)
*
|
2006-12-22 |
2009-12-23 |
恩希赛弗制药公司 |
C3a受体调节剂及其使用方法
|
|
AU2007343726A1
(en)
*
|
2006-12-26 |
2008-07-24 |
Amgen Inc. |
N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
|
|
NZ578078A
(en)
|
2007-01-16 |
2011-11-25 |
Purdue Pharma Lp |
Heterocyclic-substituted piperidine as orl-1 ligands
|
|
KR20150008922A
(ko)
|
2007-02-09 |
2015-01-23 |
메타베이시스 테라퓨틱스, 인크. |
글루카곤 수용체의 길항제
|
|
SG175611A1
(en)
|
2007-02-21 |
2011-11-28 |
Sepracor Inc |
Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
|
|
BRPI0808089A2
(pt)
|
2007-02-28 |
2014-07-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
TW200846305A
(en)
|
2007-03-15 |
2008-12-01 |
Auspex Pharmaceuticals Inc |
Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
|
|
CA2683409A1
(en)
|
2007-04-04 |
2008-10-16 |
Sigmoid Pharma Limited |
A pharmaceutical composition of tacrolimus
|
|
ES2963291T3
(es)
|
2007-04-26 |
2024-03-26 |
Sublimity Therapeutics Ltd |
Fabricación de múltiples minicápsulas
|
|
US20090176796A1
(en)
|
2007-04-27 |
2009-07-09 |
Purdue Pharma L. P. |
Trpv1 antagonists including amide substituent and uses thereof
|
|
KR20090130422A
(ko)
*
|
2007-04-27 |
2009-12-23 |
퍼듀 퍼머 엘피 |
통증 치료에 유용한 치료제
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
EP2019101A1
(de)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one nützlich als Kinase-Inhibitor
|
|
CA2688493C
(en)
|
2007-05-31 |
2016-04-19 |
Sepracor Inc. |
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
|
|
EP2166843A4
(de)
|
2007-06-01 |
2010-08-11 |
Univ Princeton |
Behandlung von virusinfektionen durch modulation von hostzellen-stoffwechselpfaden
|
|
CA2690719A1
(en)
*
|
2007-07-06 |
2009-01-15 |
Nuon Therapeutics, Inc. |
Treatment of neuropathic pain
|
|
EA201000016A1
(ru)
*
|
2007-07-12 |
2010-10-29 |
Трагара Фармасьютикалс, Инк. |
Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
|
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
|
TWI444186B
(zh)
|
2007-08-01 |
2014-07-11 |
Synta Pharmaceuticals Corp |
用於發炎與免疫相關用途之雜環－芳基化合物
|
|
EP2185514A4
(de)
|
2007-08-01 |
2011-05-18 |
Synta Pharmaceuticals Corp |
Vinylarylderivate für mit entzündungen und dem immunsystem in zusammenhang stehende anwendungen
|
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
|
MX2010001784A
(es)
|
2007-08-13 |
2010-03-15 |
Metabasis Therapeutics Inc |
Activadores novedosos de la glucocinasa.
|
|
WO2009027852A2
(en)
*
|
2007-08-28 |
2009-03-05 |
Agi Therapeutics, P.L.C. |
Methods and compositions for treating gastrointestinal conditions
|
|
JP5554709B2
(ja)
|
2007-08-31 |
2014-07-23 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
置換キノキサリンタイプピペリジン化合物とその使用
|
|
WO2009035634A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Activx Biosciences, Inc. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
|
|
BRPI0816814B1
(pt)
|
2007-09-12 |
2021-08-31 |
Kyorin Pharmaceutical Co. Ltd |
Composto, composição farmacêutica e uso de um composto
|
|
EP2200999B1
(de)
|
2007-09-26 |
2014-08-13 |
Celgene Corporation |
6-, 7- oder 8-substituierte chinazolinonderivate und zusammensetzungen, die diese enthalten, sowie verfahren zu deren anwendung
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
CN101827860A
(zh)
*
|
2007-10-16 |
2010-09-08 |
西福根有限公司 |
包含最佳化her1和her3多聚体的组合物及其使用方法
|
|
WO2009051772A1
(en)
*
|
2007-10-17 |
2009-04-23 |
Duke University |
Geranylgeranyl transferase inhibitors and methods of making and using the same
|
|
CA2702494A1
(en)
|
2007-10-19 |
2009-04-23 |
The Regents Of The University Of California |
Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
|
|
US20110223248A1
(en)
*
|
2007-12-12 |
2011-09-15 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for treating lactose intolerance
|
|
CA2709383A1
(en)
|
2007-12-14 |
2009-06-25 |
Milton L. Brown |
Histone deacetylase inhibitors
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
JP5236748B2
(ja)
|
2008-01-08 |
2013-07-17 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
疼痛治療のためのカンナビノイド受容体のリガンドとしてのプロリン類似体
|
|
EP3090743A1
(de)
|
2008-01-09 |
2016-11-09 |
Charleston Laboratories, Inc. |
Pharmazeutische zusammensetzungen
|
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
KR101601997B1
(ko)
|
2008-03-17 |
2016-03-17 |
암비트 바이오사이언시즈 코포레이션 |
Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
|
|
US8822500B2
(en)
|
2008-03-19 |
2014-09-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
|
US8815906B2
(en)
|
2008-03-19 |
2014-08-26 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
|
US9249147B2
(en)
|
2008-03-19 |
2016-02-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
|
EP2687213B1
(de)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion umfassende feste Formen, Zusammensetzungen daraus und ihre Verwendungszwecke
|
|
ES2476252T3
(es)
|
2008-03-27 |
2014-07-14 |
Celgene Corporation |
Formas sólidas que comprenden (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfoniletil]-4-acetilaminoisoindolina-1,3-diona, composiciones de las mismas y usos de las mismas
|
|
WO2009128917A2
(en)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
EP2112152A1
(de)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones als Plk-Inhibitoren
|
|
EP2112150B1
(de)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Verbesserte Raf-Inhibitoren
|
|
US9314469B2
(en)
|
2008-05-05 |
2016-04-19 |
Tonix Pharma Holdings Limited |
Method for treating neurocognitive dysfunction
|
|
DE102008022520A1
(de)
*
|
2008-05-07 |
2009-11-12 |
Bayer Animal Health Gmbh |
Feste Arzneimittelformulierung mit verzögerter Freisetzung
|
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
|
KR20110036540A
(ko)
*
|
2008-05-20 |
2011-04-07 |
쎄레니스 떼라퓨틱스 에스.에이. |
병용 요법을 위한 니아신 및 ｎｓａｉｄ
|
|
ES2732453T3
(es)
|
2008-07-01 |
2019-11-22 |
Curemark Llc |
Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
|
|
ES2458358T3
(es)
|
2008-07-02 |
2014-05-05 |
Idenix Pharmaceuticals, Inc. |
Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
|
|
PE20140102A1
(es)
|
2008-07-21 |
2014-02-06 |
Purdue Pharma Lp |
Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
|
|
US8530494B2
(en)
|
2008-07-30 |
2013-09-10 |
Purdue Pharma Lp |
Buprenophine analogs
|
|
EP2326618B1
(de)
|
2008-08-13 |
2014-10-15 |
Metabasis Therapeutics, Inc. |
Glucagon-antagonisten
|
|
EP2348863A4
(de)
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
Borhaltige kleine moleküle
|
|
JP2012502915A
(ja)
|
2008-09-15 |
2012-02-02 |
バイオビスタ インコーポレイテッド |
てんかんを治療する組成物及び方法
|
|
AU2009300317A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
|
EP2346329B1
(de)
|
2008-10-09 |
2013-08-21 |
Anadys Pharmaceuticals, Inc. |
Verfahren zur hemmung des hepatitis-c-virus mittels kombination aus einem 5,6-dihydro-1h-pyridin-2-on und einer oder mehreren antiviralen verbindungen
|
|
EP2349308A4
(de)
|
2008-10-10 |
2012-09-12 |
Purdue Research Foundation |
Verbindungen zur behandlung von morbus alzheimer
|
|
US8546388B2
(en)
*
|
2008-10-24 |
2013-10-01 |
Purdue Pharma L.P. |
Heterocyclic TRPV1 receptor ligands
|
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
|
US8703962B2
(en)
*
|
2008-10-24 |
2014-04-22 |
Purdue Pharma L.P. |
Monocyclic compounds and their use as TRPV1 ligands
|
|
EP3354646A1
(de)
|
2008-10-29 |
2018-08-01 |
Celgene Corporation |
Isoindolin-verbindungen zur behandlung von krebs
|
|
EP2376083A4
(de)
*
|
2008-11-20 |
2012-06-20 |
Purdue Research Foundation |
Chinazolin-inhibitoren von bace 1 und anwendungsverfahren
|
|
US8859590B2
(en)
|
2008-12-05 |
2014-10-14 |
Purdue Research Foundation |
Inhibitors of BACE1 and methods for treating Alzheimer's disease
|
|
RS58728B1
(sr)
|
2008-12-09 |
2019-06-28 |
Halozyme Inc |
Produženi rastvorljivi ph20 polipeptidi i njihove upotrebe
|
|
ES2421171T3
(es)
|
2008-12-16 |
2013-08-29 |
Sunovion Pharmaceuticals Inc. |
Inhibidores de reabsorción triples y su uso en métodos
|
|
WO2010075255A2
(en)
|
2008-12-22 |
2010-07-01 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating or preventing cancer and neurodegenerative diseases
|
|
WO2010075280A2
(en)
|
2008-12-22 |
2010-07-01 |
Sloan-Kettering Institute For Cancer Research |
Coumarin-based compounds
|
|
CN102307892A
(zh)
|
2008-12-31 |
2012-01-04 |
西尼克斯公司 |
环孢菌素a的衍生物
|
|
CN105664144B
(zh)
|
2009-01-06 |
2020-08-11 |
加尔纳根有限责任公司 |
治疗或预防金黄色葡萄球菌感染以及根除或减少表面上金黄色葡萄球菌的组合物和方法
|
|
AU2010203714C1
(en)
|
2009-01-06 |
2013-12-12 |
Galenagen, Llc |
Compositions and methods for the treatment or the prevention of infections by e. coli
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
ES2553612T3
(es)
|
2009-02-09 |
2015-12-10 |
Sunovion Pharmaceuticals Inc. |
Inhibidores de la recaptación triple de pirrolidina
|
|
EP2818164A1
(de)
|
2009-02-10 |
2014-12-31 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit PDE4-Modulatoren zur Behandlung, Vorbeugung und Handhabung von Tuberkulose
|
|
JP2012517471A
(ja)
|
2009-02-11 |
2012-08-02 |
スノビオン プハルマセウトイカルス インコーポレイテッド |
ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
EP2396312A1
(de)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Lenalidomidisotopologe
|
|
KR20110124780A
(ko)
|
2009-02-24 |
2011-11-17 |
리터 파마슈티컬즈 인코오포레이티드 |
프리바이오틱 제제 및 사용 방법
|
|
RU2529019C2
(ru)
|
2009-02-27 |
2014-09-27 |
Эмбит Байосайенсиз Корпорейшн |
Модулирующие jak киназу хиназолиновые производные и способы их применения
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
WO2010102262A1
(en)
|
2009-03-06 |
2010-09-10 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
|
|
CA2754909A1
(en)
|
2009-03-11 |
2010-09-16 |
Ambit Biosciences Corp. |
Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
|
|
WO2010104205A1
(en)
*
|
2009-03-11 |
2010-09-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
JP5766177B2
(ja)
|
2009-03-27 |
2015-08-19 |
ベトディーシー，インコーポレイテッド |
ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
AU2010239311B2
(en)
|
2009-04-20 |
2014-05-22 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
|
SG2014005110A
(en)
|
2009-04-22 |
2014-03-28 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide ccr3 antagonists
|
|
PE20120809A1
(es)
|
2009-04-22 |
2012-07-08 |
Axikin Pharmaceuticals Inc |
Antagonistas ccr3 arilsulfonamida 2,5-disustituidos
|
|
ES2664984T3
(es)
|
2009-04-22 |
2018-04-24 |
SMA Therapeutics, Inc. |
Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
|
|
US9968574B2
(en)
*
|
2009-05-15 |
2018-05-15 |
The University Of Kentucky Research Foundation |
Treatment of MCI and Alzheimer's disease
|
|
US20100292281A1
(en)
*
|
2009-05-15 |
2010-11-18 |
The University Of Kentucky Research Foundation |
Treatment of mci and alzheimer's disease
|
|
SG176145A1
(en)
|
2009-05-18 |
2011-12-29 |
Sigmoid Pharma Ltd |
Composition comprising oil drops
|
|
JP5645816B2
(ja)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
|
CA2764808A1
(en)
|
2009-06-10 |
2010-12-16 |
Sunovion Pharmaceuticals Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
|
JP5775071B2
(ja)
|
2009-06-16 |
2015-09-09 |
ファイザー・インク |
アピキサバンの製剤形
|
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
|
EP2532659A1
(de)
|
2009-07-07 |
2012-12-12 |
Pathway Therapeutics, Inc. |
Pyrimidinyl- und 1,3,5-Triazinyl-Benzimidazole und ihre Verwendung in der Krebstherapie
|
|
JP5905387B2
(ja)
|
2009-07-08 |
2016-04-20 |
ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズＨｏｐｅ Ｍｅｄｉｃａｌ Ｅｎｔｅｒｐｒｉｓｅｓ，Ｉｎｃ．Ｄｂａ Ｈｏｐｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ |
チオ硫酸ナトリウムを含有する薬学的組成物
|
|
EP2451274B1
(de)
|
2009-07-08 |
2017-10-04 |
Charleston Laboratories, Inc. |
Pharmazeutische zusammensetzungen
|
|
US20110020272A1
(en)
|
2009-07-24 |
2011-01-27 |
Ulrich Schubert |
Combination therapy for treating hepatitis viral infection
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP2459184A1
(de)
|
2009-07-31 |
2012-06-06 |
The Brigham and Women's Hospital, Inc. |
Modulation der sgk1-expression bei th17-zellen zur modulation von th17-vermittelten immunreaktionen
|
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
|
US9878036B2
(en)
|
2009-08-12 |
2018-01-30 |
Sigmoid Pharma Limited |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
|
WO2011022473A1
(en)
|
2009-08-19 |
2011-02-24 |
Ambit Biosciences Corporation |
Biaryl compounds and methods of use thereof
|
|
EP2473038A4
(de)
|
2009-09-04 |
2013-10-23 |
United Paragon Associates Inc |
Zusammensetzungen zur behandlung von durch neurokinin-2-rezeptor-aktivität vermittelten leiden oder erkrankungen
|
|
US20120172350A1
(en)
|
2009-09-11 |
2012-07-05 |
Sunovion Pharmaceuticals Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
|
US20110136751A1
(en)
|
2009-10-06 |
2011-06-09 |
Green Molecular |
Use of Polyphenols in the Treatment of Cancer
|
|
RS53716B1
(en)
|
2009-10-19 |
2015-04-30 |
Synta Pharmaceuticals Corp. |
COMBINED CANCER THERAPY WITH HSP90 INHIBITORS
|
|
US8470817B2
(en)
*
|
2009-10-26 |
2013-06-25 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
|
EP2325185A1
(de)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk-Inhibitor
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011063102A1
(en)
|
2009-11-19 |
2011-05-26 |
Celgene Corporation |
Apremilast for the treatment of sarcoidosis
|
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
|
PT2501234T
(pt)
*
|
2009-11-20 |
2017-12-13 |
Tonix Pharma Holdings Ltd |
Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
|
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
NZ731621A
(en)
|
2009-12-04 |
2019-01-25 |
Sunovion Pharmaceuticals Inc |
Multicyclic compounds and methods of use thereof
|
|
BR112012013325B8
(pt)
|
2009-12-04 |
2021-05-25 |
Sunovion Pharmaceuticals Inc |
composição farmacêutica e uso
|
|
CN102869367A
(zh)
|
2009-12-09 |
2013-01-09 |
西尼克斯公司 |
新颖的环肽
|
|
CA2784748A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
WO2011079091A1
(en)
|
2009-12-22 |
2011-06-30 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
|
EP2515864A4
(de)
*
|
2009-12-23 |
2013-09-11 |
Psivida Inc |
Vorrichtung mit verzögerter freisetzung
|
|
EP2515654A4
(de)
*
|
2009-12-23 |
2013-04-24 |
Map Pharmaceuticals Inc |
Neue ergolinanaloga
|
|
CN102834409A
(zh)
|
2009-12-30 |
2012-12-19 |
西尼克斯公司 |
环孢菌素类似物
|
|
EP2521537A2
(de)
|
2010-01-04 |
2012-11-14 |
Wockhardt Limited |
Pharmazeutische zusammensetzung zur modifizierten freisetzung von wirkstoffen
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
HRP20221208T1
(hr)
|
2010-01-04 |
2022-12-09 |
Mapi Pharma Limited |
Depot sustav koji sadrži glatiramer acetat
|
|
EP2521543B1
(de)
|
2010-01-05 |
2016-04-13 |
Celgene Corporation |
Kombination aus einer immunmodulatorischen verbindung und einem artemisinin derivat zur behandlung von krebs
|
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
UA115523C2
(uk)
|
2010-02-05 |
2017-11-27 |
Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" |
Тверді форми макроциклічних інгібіторів кінази
|
|
EP3202460B1
(de)
|
2010-02-11 |
2019-06-12 |
Celgene Corporation |
Arylmethoxyisoindolinderivate, zusammensetzungen damit und verfahren zur verwendung davon
|
|
AU2011223873B2
(en)
|
2010-03-02 |
2015-06-25 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
AR080505A1
(es)
|
2010-03-12 |
2012-04-11 |
Celgene Corp |
Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores
|
|
TW201134820A
(en)
|
2010-03-17 |
2011-10-16 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide CCR3 antagonists
|
|
JP2013522321A
(ja)
|
2010-03-19 |
2013-06-13 |
パーデュー・リサーチ・ファウンデーション |
Ｈｉｖを治療するためのｃｃｒ５モジュレーター
|
|
WO2011127019A2
(en)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
|
CA2794565C
(en)
|
2010-04-08 |
2018-08-21 |
Emory University |
Substituted androst-4-ene diones
|
|
WO2011133520A1
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
WO2011133521A2
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
|
EP2563372A4
(de)
|
2010-04-28 |
2013-10-02 |
Ritter Pharmaceuticals Inc |
Präbiotische formulierungen und verwendungsverfahren dafür
|
|
WO2011140360A1
(en)
|
2010-05-05 |
2011-11-10 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled compounds and uses thereof
|
|
WO2011146803A1
(en)
|
2010-05-20 |
2011-11-24 |
Synta Pharmaceuticals Corp. |
Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
|
|
US20120064175A1
(en)
|
2010-05-20 |
2012-03-15 |
Synta Pharmaceuticals Corp. |
HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients
|
|
US20130171105A1
(en)
|
2010-05-24 |
2013-07-04 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
|
WO2011150156A2
(en)
|
2010-05-26 |
2011-12-01 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
EP2576520A1
(de)
|
2010-05-28 |
2013-04-10 |
GE Healthcare UK Limited |
Radioaktiv markierte verbindungen und ihre verfahren
|
|
AU2011261501B2
(en)
|
2010-06-01 |
2016-01-21 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
|
|
JP5844354B2
(ja)
|
2010-06-01 |
2016-01-13 |
ビオトヘルイク， インコーポレイテッド |
ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
|
|
CA2801778C
(en)
|
2010-06-07 |
2018-06-05 |
Novomedix, Llc |
Furanyl compounds and the use thereof
|
|
US20110319389A1
(en)
|
2010-06-24 |
2011-12-29 |
Tonix Pharmaceuticals, Inc. |
Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
|
|
WO2012012370A1
(en)
|
2010-07-19 |
2012-01-26 |
Summa Health System |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
|
US20140200270A1
(en)
|
2013-01-11 |
2014-07-17 |
Summa Health System |
Vitamins c and k for treating polycystic diseases
|
|
CN103153295A
(zh)
|
2010-08-24 |
2013-06-12 |
艾格埃克斯制药有限公司 |
来氟米特和丙二腈酰胺类似物的新用途
|
|
EP2611793A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cyclochinazolinderivate und verwendungsverfahren dafür
|
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
JP5901634B2
(ja)
|
2010-09-01 |
2016-04-13 |
アムビト ビオスシエンセス コルポラチオン |
キナゾリン化合物及びその使用方法
|
|
EP2611812A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridin- und thienopyrimidinverbindungen sowie verfahren zu ihrer verwendung
|
|
WO2012030913A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
US20120053176A1
(en)
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
KR20130141469A
(ko)
|
2010-09-01 |
2013-12-26 |
암비트 바이오사이언시즈 코포레이션 |
피라졸릴아미노퀴나졸린의 브롬화수소 염
|
|
EP2611448A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
7-cyclylchinazolinderivate und verwendungsverfahren dafür
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
WO2012042314A1
(en)
|
2010-10-02 |
2012-04-05 |
Link Research & Grants Corporation |
Treatment of tinnitus and related auditory dysfunctions
|
|
MX2013003954A
(es)
|
2010-10-11 |
2013-08-01 |
Axikin Pharmaceuticals Inc |
Sales de arilsulfonamida antagonistas de ccr3.
|
|
BR112013009196A2
(pt)
|
2010-10-15 |
2020-08-25 |
The Trustees Of Columbia University In The City Of New York |
usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
|
|
US20120090857A1
(en)
*
|
2010-10-15 |
2012-04-19 |
Baker Hughes Incorporated |
Swellable Member, Swell Controlling Arrangement and Method of Controlling Swelling of a Swellable Member
|
|
NZ718514A
(en)
|
2010-10-18 |
2017-10-27 |
Cerenis Therapeutics Holding Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
|
CA2815024A1
(en)
|
2010-10-19 |
2012-04-26 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
|
CN103179962B
(zh)
|
2010-10-29 |
2017-03-22 |
艾格埃克斯制药有限公司 |
丙二腈酰胺类似物在神经病理性疼痛中的用途
|
|
US20130289071A1
(en)
|
2010-11-09 |
2013-10-31 |
Synta Pharmaceuticals Corp. |
Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
|
|
CN103298474B
(zh)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
BR112013014021A8
(pt)
|
2010-12-06 |
2017-10-03 |
Follica Inc |
Métodos para tratamento de calvície e promoção de crescimento de cabelos
|
|
WO2012078757A2
(en)
|
2010-12-08 |
2012-06-14 |
Synta Pharmaceuticals Corp. |
Combination breast cancer therapy with hsp90 inhibitory compounds
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
|
CN103442698B
(zh)
|
2010-12-16 |
2016-10-05 |
细胞基因公司 |
难溶性药物的控释口服剂量形式及其用途
|
|
EP2654751B1
(de)
|
2010-12-22 |
2016-11-23 |
Purdue Pharma L.P. |
Phosphorsubstituierte quinoxalin-piperidinverbindungen und verwendungen davon
|
|
WO2013103919A2
(en)
|
2012-01-06 |
2013-07-11 |
Elcelyx Therapeutics, Inc. |
Compositions and methods for treating metabolic disorders
|
|
KR20140035331A
(ko)
|
2011-01-07 |
2014-03-21 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
화학감각 수용체 리간드-기반 요법
|
|
CN103391770A
(zh)
|
2011-01-10 |
2013-11-13 |
细胞基因公司 |
环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
|
|
WO2012097000A1
(en)
|
2011-01-10 |
2012-07-19 |
Pingda Ren |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
|
CN103402980B
(zh)
|
2011-01-10 |
2016-06-29 |
细胞基因公司 |
作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
|
|
EP2663305A1
(de)
|
2011-01-11 |
2013-11-20 |
Synta Pharmaceuticals Corp. |
Kombinationstherapie aus hsp90-hemmenden verbindungen und proteasom-hemmern
|
|
JP6106603B2
(ja)
|
2011-01-11 |
2017-04-05 |
スノビオン プハルマセウトイカルス インコーポレイテッド |
ヘテロアリール化合物及びその使用方法
|
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
|
EP2665477B1
(de)
|
2011-01-20 |
2015-09-09 |
Bionevia Pharmaceuticals Inc. |
Zusammensetzungen mit veränderter freisetzung von epalrestat oder einem derivat davon und verwendungsverfahren dafür
|
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
|
EP2670426B1
(de)
|
2011-01-31 |
2017-05-10 |
The General Hospital Corporation |
Multimodale trail-moleküle und ihre verwendungen in zelltherapien
|
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
|
WO2012116061A1
(en)
|
2011-02-23 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with radiotherapy
|
|
CA2827336C
(en)
|
2011-02-23 |
2016-01-26 |
Coeruleus Ltd. |
Flumazenil complexes, compositions comprising same and uses thereof
|
|
AU2012243289A1
(en)
|
2011-02-24 |
2013-08-29 |
Synta Pharmaceuticals Corp. |
Prostate cancer therapy with Hsp90 inhibitory compounds
|
|
US20140045908A1
(en)
|
2011-02-25 |
2014-02-13 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
|
WO2012121988A2
(en)
|
2011-03-07 |
2012-09-13 |
Celgene Corporation |
Methods for treating diseases using isoindoline compounds
|
|
US11998516B2
(en)
|
2011-03-07 |
2024-06-04 |
Tonix Pharma Holdings Limited |
Methods and compositions for treating depression using cyclobenzaprine
|
|
RU2013145556A
(ru)
|
2011-03-11 |
2015-04-20 |
Селджин Корпорейшн |
Применение 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2,6-диона в лечении иммунных и воспалительных заболеваний
|
|
CN103562197B
(zh)
|
2011-03-11 |
2016-05-11 |
细胞基因公司 |
3-(5-氨基-2-甲基-4-氧-4h-喹唑啉-3-基)-哌啶-2,6-二酮的固体形式及其药物组合物和用途
|
|
EP2685983B1
(de)
|
2011-03-17 |
2016-05-18 |
Algiax Pharmaceuticals GmbH |
Neue verwendung von imidazotriazinonen
|
|
EP2685975A1
(de)
|
2011-03-17 |
2014-01-22 |
Algiax Pharmaceuticals GmbH |
Neue verwendung von benzofuranylsulfonaten
|
|
CA2830069C
(en)
|
2011-03-20 |
2019-11-12 |
The University Of British Columbia |
Therapeutic agent for emphysema and copd
|
|
WO2012135175A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
WO2012135166A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
ES2608967T3
(es)
|
2011-03-28 |
2017-04-17 |
Mei Pharma, Inc. |
(Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
|
|
WO2012135299A1
(en)
|
2011-03-28 |
2012-10-04 |
Deuteria Pharmaceuticals Inc |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
JP2014514295A
(ja)
|
2011-03-31 |
2014-06-19 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
WO2012158271A1
(en)
|
2011-04-06 |
2012-11-22 |
Anadys Pharmaceuticals, Inc. |
Bridged polycyclic compounds as antiviral agents
|
|
WO2012144463A1
(ja)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
AU2012245287B2
(en)
|
2011-04-21 |
2017-04-13 |
Curemark, Llc |
Compounds for the treatment of neuropsychiatric disorders
|
|
EP2699317B1
(de)
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Zufallspentapolymer zur behandlung von autoimmunkrankheiten
|
|
JP6022548B2
(ja)
|
2011-04-28 |
2016-11-09 |
セルジーン コーポレイション |
Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
|
|
KR20140024914A
(ko)
|
2011-04-29 |
2014-03-03 |
셀진 코포레이션 |
예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
|
|
JP5985611B2
(ja)
|
2011-05-03 |
2016-09-06 |
シンタ ファーマシューティカルズ コーポレーション |
炎症および免疫関連用途のための化合物
|
|
EP2704726B1
(de)
|
2011-05-04 |
2018-10-31 |
Trustees of Boston University |
Protonenantriebskraftstimulation zur potenzierung von aminoglycosid-antibiotika gegen persistente bakterien
|
|
WO2012162372A1
(en)
|
2011-05-24 |
2012-11-29 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
|
|
WO2012166586A1
(en)
|
2011-05-27 |
2012-12-06 |
Temple University - Of The Commonwealth System Of Higher Education |
SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF
|
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
EP2718273A4
(de)
|
2011-06-07 |
2014-12-10 |
Anadys Pharmaceuticals Inc |
[1,2,4]-thiadiazin-1,1-dioxidverbindungen zur senkung des harnsäurespiegels im serum
|
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
|
KR20150055094A
(ko)
|
2011-06-22 |
2015-05-20 |
퍼듀 퍼머 엘피 |
디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도
|
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
|
WO2013006864A2
(en)
|
2011-07-07 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
|
EP2734530A1
(de)
|
2011-07-19 |
2014-05-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclische verbindungen und ihre verwendung
|
|
EP2734520B1
(de)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclische verbindungen und ihre verwendung
|
|
GB201112987D0
(en)
|
2011-07-28 |
2011-09-14 |
Ge Healthcare Ltd |
Novel compound
|
|
US9394293B2
(en)
|
2011-08-10 |
2016-07-19 |
Purdue Pharma L.P. |
TRPV1 antagonists including dihydroxy substituent and uses thereof
|
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
|
EP2741760A2
(de)
|
2011-08-12 |
2014-06-18 |
B.S.R.C. "Alexander Fleming" |
Trimerisierungsinhibitoren der tnf-superfamilie
|
|
EA201490472A1
(ru)
|
2011-08-19 |
2014-05-30 |
Синта Фармасьютиклз Корп. |
Комбинированная терапия рака hsp90-ингибитором и антиметаболитом
|
|
DK2959899T3
(en)
|
2011-08-23 |
2017-05-01 |
Cornerstone Therapeutics Inc |
Use of zileuton for the treatment of nasal polyps in patients with cystic fibrosis
|
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
EP2755985B1
(de)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
|
|
TW201329096A
(zh)
|
2011-09-12 |
2013-07-16 |
Idenix Pharmaceuticals Inc |
經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
|
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
|
CA2849708A1
(en)
|
2011-09-23 |
2013-03-28 |
Celgene Corporation |
Romidepsin and 5 - azacitidine for use in treating lymphoma
|
|
EP2760456A1
(de)
|
2011-09-26 |
2014-08-06 |
Celgene Corporation |
Kombinationstherapie für chemoresistente tumoren
|
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
|
WO2013051001A1
(en)
|
2011-10-06 |
2013-04-11 |
Yeda Research And Development Co. Ltd. |
Combination therapy with erbb ligands binding molecules
|
|
EP2764406B1
(de)
|
2011-10-07 |
2018-03-14 |
Cedars-Sinai Medical Center |
Zusammensetzungen und verfahren für tumorbildgebung und -anzielung mit einer klasse organischer heptamethincyaninfarbstoffe mit nuklear- und nahinfrarot-eigenschaften
|
|
US20140271657A1
(en)
|
2011-10-12 |
2014-09-18 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
|
AR089650A1
(es)
|
2011-10-14 |
2014-09-10 |
Idenix Pharmaceuticals Inc |
Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
PL2766359T3
(pl)
|
2011-10-14 |
2016-11-30 |
|
Związki heterocykliczne i ich zastosowanie jako modulatorów receptorowych kinaz tyrozynowych typu iii
|
|
SG11201401946QA
(en)
|
2011-11-01 |
2014-05-29 |
Celgene Corp |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とｈｓｐ９０阻害剤の組合せ療法
|
|
WO2013071049A1
(en)
|
2011-11-10 |
2013-05-16 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
|
US9402831B2
(en)
|
2011-11-14 |
2016-08-02 |
Synta Pharmaceutical Corp. |
Combination therapy of HSP90 inhibitors with BRAF inhibitors
|
|
WO2013080036A1
(en)
|
2011-12-01 |
2013-06-06 |
Purdue Pharma L.P. |
Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
|
WO2013084060A1
(en)
|
2011-12-08 |
2013-06-13 |
Purdue Pharma L.P. |
Quaternized buprenorphine analogs
|
|
WO2013095707A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
SG11201403433PA
(en)
|
2011-12-21 |
2014-07-30 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
|
BR112014016195A2
(pt)
|
2011-12-30 |
2020-10-27 |
Halozyme, Inc. |
variantes de polipeptídio ph20, formulações e usos das mesmas
|
|
DK2800578T3
(en)
|
2012-01-05 |
2019-03-25 |
Boston Medical Ct Corp |
SLIT-ROBO SIGNAL FOR DIAGNOSIS AND TREATMENT OF Kidney Diseases
|
|
KR102035879B1
(ko)
|
2012-01-06 |
2019-10-23 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
바이구아나이드 조성물 및 대사 장애를 치료하는 방법
|
|
CA2864085C
(en)
|
2012-02-08 |
2021-11-23 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
|
ES2671608T3
(es)
|
2012-02-21 |
2018-06-07 |
Celgene Corporation |
Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
|
|
US20150018362A1
(en)
|
2012-02-27 |
2015-01-15 |
Biovista, Inc. |
Compositions and methods for treating mitochondrial diseases
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
WO2013133708A1
(en)
|
2012-03-07 |
2013-09-12 |
Stichting Vu-Vumc |
Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
|
|
AU2013205240B2
(en)
|
2012-03-16 |
2016-02-11 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
CA2901394A1
(en)
|
2012-03-19 |
2013-09-26 |
The Brigham And Women's Hosptial, Inc. |
Growth differentiation factor (gdf) for treatment of diastolic heart failure
|
|
WO2013139861A1
(en)
|
2012-03-20 |
2013-09-26 |
Luc Montagnier |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
|
US9169207B2
(en)
|
2012-03-27 |
2015-10-27 |
Incuron, Llc |
Curaxins for use in treating carcinogen-induced cancer
|
|
CA2868258A1
(en)
|
2012-03-28 |
2013-10-03 |
Synta Pharmaceuticals Corp. |
Triazole derivatives as hsp90 inhibitors
|
|
WO2013152206A1
(en)
|
2012-04-04 |
2013-10-10 |
Synta Pharmaceuticals Corp. |
Novel triazole compounds that modulate hsp90 activity
|
|
JP6042527B2
(ja)
|
2012-04-04 |
2016-12-14 |
ハロザイム インコーポレイテッド |
抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
|
US8946253B2
(en)
|
2012-04-17 |
2015-02-03 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
|
EP3338776A1
(de)
|
2012-05-01 |
2018-06-27 |
Translatum Medicus Inc. |
Verfahren zur behandlung und diagnose von erblindenden augenerkrankungen
|
|
US20150099721A1
(en)
|
2012-05-10 |
2015-04-09 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
|
GB201208315D0
(en)
|
2012-05-11 |
2012-06-27 |
Numedicus Ltd |
Pharmaceutical methods and compositions
|
|
AR091027A1
(es)
|
2012-05-11 |
2014-12-30 |
Purdue Pharma Lp |
Analogos de benzomorfano y el usos de estos
|
|
MD20140134A2
(ro)
|
2012-05-22 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
|
|
EP2852605B1
(de)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclische phosphat-prodrugs für hcv-infektion
|
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP3406598B1
(de)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Pyrazolderivate als hemmer von stat3
|
|
WO2013188763A1
(en)
|
2012-06-15 |
2013-12-19 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9857359B2
(en)
|
2012-06-29 |
2018-01-02 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
|
AU2013290100A1
(en)
|
2012-07-11 |
2015-01-29 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
|
US9034870B2
(en)
|
2012-07-13 |
2015-05-19 |
Purdue Research Foundation |
Azaindenoisoquinoline topoisomerase I inhibitors
|
|
US9085561B2
(en)
|
2012-07-30 |
2015-07-21 |
Purdue Pharma L.P. |
Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
|
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
EP3741372A1
(de)
|
2012-08-09 |
2020-11-25 |
Celgene Corporation |
(s)-3-[4-(4-morphlin-4-ylmethylbenzyloxy)-1- oxo-1,3-dihydro-isoindo-2-yl]piperidine-2,6-dione zur behandlung von immunbedingten entzündungserkrankungen
|
|
EP3524598B1
(de)
|
2012-08-09 |
2021-07-07 |
Celgene Corporation |
Eine feste form des (s)3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorids
|
|
TWI723266B
(zh)
|
2012-08-09 |
2021-04-01 |
美商西建公司 |
利用3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)六氫吡啶-2,6-二酮治療癌症之方法
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
US10624859B2
(en)
|
2012-08-20 |
2020-04-21 |
Rhodes Technologies |
Systems and methods for increasing stability of dronabinol compositions
|
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
|
EP2890720B1
(de)
|
2012-08-30 |
2019-07-17 |
The General Hospital Corporation |
Zusammensetzungen und verfahren zur behandlung von krebs
|
|
WO2014036528A2
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
|
JP2015527396A
(ja)
|
2012-09-07 |
2015-09-17 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
同位体濃縮されたアリールスルホンアミドｃｃｒ３アンタゴニスト
|
|
CN104797256A
(zh)
|
2012-09-10 |
2015-07-22 |
细胞基因公司 |
用于治疗局部晚期乳腺癌的方法
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
MX353422B
(es)
|
2012-10-08 |
2018-01-12 |
Idenix Pharmaceuticals Llc |
Análogos de 2'-cloronucleósido para infección por vhc.
|
|
BR112015008118A2
(pt)
|
2012-10-12 |
2017-12-05 |
Brigham & Womens Hospital Inc |
reforço da resposta imune
|
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
EP2909223B1
(de)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinukleotidverbindungen für hcv-infektion
|
|
EP2909222B1
(de)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-verbrückten nukleoside für hcv-infektion
|
|
JP6584952B2
(ja)
|
2012-11-01 |
2019-10-02 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
|
|
CA2890177A1
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
WO2014074846A1
(en)
|
2012-11-09 |
2014-05-15 |
Celgene Corporation |
Methods for the treatment of bone loss
|
|
TW201431842A
(zh)
|
2012-11-09 |
2014-08-16 |
Purdue Pharma Lp |
苯並嗎啡烷類似物及其應用
|
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
|
EP2920195A1
(de)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
D-alaninester eines rp-nukleosidanalogons
|
|
WO2014085284A1
(en)
|
2012-11-29 |
2014-06-05 |
Sunovion Pharmaceuticals Inc. |
Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
|
|
CN107698470A
(zh)
|
2012-11-30 |
2018-02-16 |
诺沃梅迪科斯有限公司 |
取代的二芳基磺酰胺及其用途
|
|
JP6317755B2
(ja)
|
2012-12-07 |
2018-04-25 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
|
|
JP6141444B2
(ja)
|
2012-12-14 |
2017-06-07 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
スピロ環式モルフィナンおよびこれらの使用
|
|
EP2931725B1
(de)
|
2012-12-14 |
2017-02-15 |
Purdue Pharma LP |
Stickstoffhaltige morphinanderivate und verwendung davon
|
|
WO2014091295A1
(en)
|
2012-12-14 |
2014-06-19 |
Purdue Pharma L.P. |
Pyridonemorphinan analogs and biological activity on opioid receptors
|
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
|
WO2014100354A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
|
WO2014102592A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
|
|
WO2014102588A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Indole and indoline-type piperidine compounds and uses thereof
|
|
WO2014102594A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted benzimidazole-type piperidine compounds and uses thereof
|
|
WO2014102589A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
|
|
WO2014102590A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted piperidin-4-amino-type compounds and uses thereof
|
|
WO2014102587A1
(en)
|
2012-12-28 |
2014-07-03 |
Purdue Pharma L.P. |
7,8-cyclicmorphinan analogs
|
|
WO2014102593A1
(en)
|
2012-12-28 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted morphinans and the use thereof
|
|
AU2013369649B2
(en)
|
2012-12-31 |
2018-07-26 |
Sunovion Pharmaceuticals Inc. |
Heterocyclic compounds and methods of use thereof
|
|
SG11201505240QA
(en)
|
2013-01-05 |
2015-08-28 |
Elcelyx Therapeutics Inc |
Delayed-release composition comprising biguanide
|
|
US20150196625A9
(en)
|
2013-01-07 |
2015-07-16 |
Rudolph D. Paladini |
Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
|
|
US9617607B2
(en)
|
2013-01-08 |
2017-04-11 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
|
WO2014110127A1
(en)
|
2013-01-08 |
2014-07-17 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
|
JP6359563B2
(ja)
|
2013-01-14 |
2018-07-18 |
デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ |
３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
|
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
|
JP6406713B2
(ja)
|
2013-01-30 |
2018-10-17 |
ファーモレックス セラピューティクス， インコーポレイテッド |
低用量薬剤によるうつ病および他の疾患の処置
|
|
EP2951160B1
(de)
|
2013-01-31 |
2019-04-24 |
Purdue Pharma LP |
Benzomorphan-analoga und verwendung davon
|
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
|
AU2014235273A1
(en)
|
2013-03-14 |
2015-07-09 |
Celgene Corporation |
Treatment of psoriatic arthritis using apremilast
|
|
SG11201507101XA
(en)
|
2013-03-15 |
2015-10-29 |
Univ California |
Acyclic nucleoside phosphonate diesters
|
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
|
CA2904812C
(en)
|
2013-03-15 |
2021-07-20 |
Tonix Pharmaceuticals, Inc. |
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
|
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
EP2981542B1
(de)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluor-nukleoside zur behandlung von hcv
|
|
BR112015025252A2
(pt)
|
2013-04-02 |
2017-07-18 |
Celgene Corp |
métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
|
|
US10092627B2
(en)
|
2013-04-08 |
2018-10-09 |
President And Fellows Of Harvard College |
Methods and compositions for rejuvenating skeletal muscle stem cells
|
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
EP3003309B1
(de)
|
2013-05-30 |
2020-09-09 |
Infinity Pharmaceuticals, Inc. |
Behandlung von krebs mit pi3-kinase-isoformmodulatoren
|
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
|
WO2014197744A1
(en)
|
2013-06-05 |
2014-12-11 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
WO2014197835A2
(en)
|
2013-06-06 |
2014-12-11 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
|
EP3007719B1
(de)
|
2013-06-11 |
2021-03-17 |
President and Fellows of Harvard College |
Verfahren und zusammensetzungen zur erhöhung der neurogenese und angiogenese
|
|
US10017531B2
(en)
|
2013-06-14 |
2018-07-10 |
Invictus Oncology Pvt. Ltd. |
Lipid-based platinum-N-heterocyclic carbene compounds and nanoparticles
|
|
EP2815749A1
(de)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
|
|
WO2014210596A1
(en)
|
2013-06-28 |
2014-12-31 |
Purdue Pharma L.P. |
Treating an arrhythmia with an opioid antagonist
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
WO2015027146A1
(en)
|
2013-08-22 |
2015-02-26 |
The General Hospital Corporation |
Inhibitors of human 12/15-lipoxygenase
|
|
US11382883B2
(en)
|
2013-08-29 |
2022-07-12 |
Trustees Of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
|
RU2016111675A
(ru)
|
2013-08-30 |
2017-10-04 |
Эмбит Байосайенсиз Корпорейшн |
Соединения биарилацетамида и способы их применения
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
ES2729642T3
(es)
|
2013-09-24 |
2019-11-05 |
Purdue Pharma Lp |
Tratamiento del dolor por quemaduras mediante moduladores de TRPV1
|
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
DK3052485T3
(da)
|
2013-10-04 |
2021-10-11 |
Infinity Pharmaceuticals Inc |
Heterocykliske forbindelser og anvendelser deraf
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3683321B1
(de)
|
2013-10-21 |
2021-12-08 |
The General Hospital Corporation |
Verfahren im zusammenhang mit zirkulierenden tumorzellclustern und mit der behandlung von krebs
|
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
WO2015065876A1
(en)
|
2013-10-29 |
2015-05-07 |
Thomas Jefferson University |
Methods of prevention or treatment for pathologic thrombosis or inflammation
|
|
EP3063165A1
(de)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanin-phosphoramidat-pronukleotide von 2'-methyl-2'-fluor-guanosin-nukleosid-verbindungen zur behandlung von hcv
|
|
GB201319792D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
|
MY184225A
(en)
|
2013-11-11 |
2021-03-28 |
Naturex Inc |
Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
|
|
EP4053560A1
(de)
|
2013-11-26 |
2022-09-07 |
The Brigham and Women's Hospital, Inc. |
Zusammensetzungen und verfahren zur modulierung einer immunreaktion
|
|
WO2015081133A2
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
Nucleotides for the treatment of liver cancer
|
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
ES2912283T3
(es)
|
2013-12-11 |
2022-05-25 |
Massachusetts Gen Hospital |
Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
|
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
|
CA2934344A1
(en)
|
2013-12-20 |
2015-06-25 |
David T. TING |
Methods and assays relating to circulating tumor cells
|
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
|
WO2015097546A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Propellane-based compounds and their use as opioid receptor modulators
|
|
WO2015097548A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
7-beta-alkyl analogs of orvinols
|
|
EP3087073B1
(de)
|
2013-12-26 |
2018-07-04 |
Purdue Pharma LP |
10-substituierte morphinanhydantoine
|
|
US9862726B2
(en)
|
2013-12-26 |
2018-01-09 |
Purdue Pharma L.P. |
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
|
|
US10550088B2
(en)
|
2013-12-27 |
2020-02-04 |
Purdue Pharma L.P. |
6-substituted and 7-substituted morphinan analogs and the use thereof
|
|
EP3089978B1
(de)
|
2013-12-30 |
2018-08-29 |
Purdue Pharma L.P. |
Pyridonsulfonmorphinan-analoga als opioidrezeptorliganden
|
|
WO2015109037A1
(en)
|
2014-01-15 |
2015-07-23 |
Deuterx, Llc |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
|
WO2015112568A1
(en)
|
2014-01-24 |
2015-07-30 |
Celgene Corporation |
Methods for the treatment of obesity using apremilast
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
WO2015138420A1
(en)
|
2014-03-10 |
2015-09-17 |
Kadmon Corporation, Llc |
Treatment of brain and central nervous system tumors
|
|
PL3119744T3
(pl)
|
2014-03-18 |
2019-07-31 |
Algiax Pharmaceuticals Gmbh |
Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
|
|
SG11201607705XA
(en)
|
2014-03-19 |
2016-10-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
US11369588B2
(en)
|
2014-03-20 |
2022-06-28 |
The Trustees Of Princeton University |
NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
|
|
CN106661027B
(zh)
|
2014-03-20 |
2019-12-24 |
卡佩拉医疗公司 |
苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
|
|
CA2943220C
(en)
|
2014-03-20 |
2024-01-16 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
US20170107300A1
(en)
|
2014-03-21 |
2017-04-20 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
|
BR112016022499A2
(pt)
|
2014-04-03 |
2017-08-15 |
Invictus Oncology Pvt Ltd |
Produtos terapêuticos combinatórios supramoleculares
|
|
WO2015153841A1
(en)
|
2014-04-04 |
2015-10-08 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for microbiome alteration
|
|
CA2944549A1
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxin useful for the treatment of pain
|
|
EP3131914B1
(de)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
|
|
CA2983794A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
|
CA2983796A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
EP3444011A1
(de)
|
2014-05-12 |
2019-02-20 |
Conatus Pharmaceuticals, Inc. |
Behandlung der komplikationen von chronischer lebererkrankung mit emricasan
|
|
WO2015175773A1
(en)
|
2014-05-15 |
2015-11-19 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
|
EP3142663A1
(de)
|
2014-05-16 |
2017-03-22 |
Celgene Corporation |
Zusammensetzungen und verfahren zur behandlung von arteriosklerotischen herz-kreislauf-erkrankungen mit pde4-modulatoren
|
|
JP6817073B2
(ja)
|
2014-05-19 |
2021-01-20 |
ノースイースタン ユニバーシティ |
セロトニン受容体を標的にする化合物および方法
|
|
EP3145500A1
(de)
|
2014-05-23 |
2017-03-29 |
Sigmoid Pharma Limited |
Zur behandlung von kolorektalem krebs nützliche celecoxibformulierungen
|
|
CA2947939A1
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
|
AU2015270925A1
(en)
|
2014-06-02 |
2016-12-22 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
|
WO2015191900A1
(en)
|
2014-06-12 |
2015-12-17 |
Ligand Pharmaceuticals, Inc. |
Glucagon antagonists
|
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
HUE042390T2
(hu)
|
2014-06-19 |
2019-06-28 |
Ariad Pharma Inc |
Heteroaril vegyületek kinázgátlásra
|
|
US10300042B2
(en)
|
2014-06-23 |
2019-05-28 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
|
EP3827836A1
(de)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Zusammensetzungen und verfahren zur induktion von konformationsänderungen bei cereblon und anderen e3-ubiquitin-ligasen
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
CN114470207B
(zh)
|
2014-08-01 |
2023-09-19 |
布里格姆及妇女医院股份有限公司 |
与肺动脉高压的治疗有关的组合物和方法
|
|
EP3188745A1
(de)
|
2014-08-15 |
2017-07-12 |
Celgene Corporation |
Dosierungstitrierung von apremilast zur behandlung von durch pde4-hemmung gelinderte krankheiten
|
|
CN107073115A
(zh)
|
2014-08-22 |
2017-08-18 |
细胞基因公司 |
用免疫调节化合物与抗体组合治疗多发性骨髓瘤的方法
|
|
ES2926687T3
(es)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y método para su producción
|
|
TR201907471T4
(tr)
|
2014-08-28 |
2019-06-21 |
Halozyme Inc |
Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
|
|
KR20170070022A
(ko)
|
2014-08-29 |
2017-06-21 |
칠드런'즈 메디컬 센터 코포레이션 |
암의 치료를 위한 방법 및 조성물
|
|
SG10201902137PA
(en)
|
2014-09-12 |
2019-04-29 |
Tobira Therapeutics Inc |
Cenicriviroc combination therapy for the treatment of fibrosis
|
|
HUE059067T2
(hu)
|
2014-09-15 |
2022-10-28 |
Univ California |
Nukleotid analógok
|
|
CN107072968B
(zh)
|
2014-09-18 |
2021-01-12 |
通尼克斯制药控股有限公司 |
环苯扎林盐酸盐的低共熔混合物配制剂
|
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ－サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
|
EP3206708B1
(de)
|
2014-10-16 |
2022-11-02 |
Cleveland Biolabs, Inc. |
Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit strahlung
|
|
PT3209647T
(pt)
|
2014-10-21 |
2020-09-10 |
Ariad Pharma Inc |
Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
|
|
EP3209658A1
(de)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoidderivate und verfahren zur verwendung
|
|
EP3881829A1
(de)
|
2014-11-07 |
2021-09-22 |
Sublimity Therapeutics Limited |
Cyclosporin enthaltende zusammensetzungen
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
EA201791346A1
(ru)
|
2014-12-16 |
2018-01-31 |
Селджин Корпорейшн |
ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
|
|
NZ733950A
(en)
|
2014-12-23 |
2018-08-31 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
|
JP7152156B2
(ja)
|
2015-01-14 |
2022-10-12 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
抗ｌａｐモノクローナル抗体による癌の処置
|
|
JP2018502889A
(ja)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
イソエルゴリン化合物およびその使用
|
|
AU2016209492B2
(en)
|
2015-01-20 |
2020-10-22 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
|
WO2016130502A1
(en)
|
2015-02-09 |
2016-08-18 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
|
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
|
WO2016142877A1
(en)
|
2015-03-10 |
2016-09-15 |
Rhodes Technologies |
Acetate salt of buprenorphine and methods for preparing buprenorphine
|
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
|
CN114366802A
(zh)
|
2015-04-22 |
2022-04-19 |
西达-赛奈医疗中心 |
用于治疗2型糖尿病的肠内递送的苦味寡肽
|
|
US10253024B2
(en)
|
2015-04-30 |
2019-04-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Polycyclic indoline and indolenine compounds
|
|
WO2016189055A1
(en)
|
2015-05-27 |
2016-12-01 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of cancer
|
|
EP3303286B1
(de)
|
2015-06-01 |
2023-10-04 |
Cedars-Sinai Medical Center |
An rela von nf-kb anbindende verbindungen zur verwendung bei der behandlung von krebs
|
|
WO2016202721A1
(en)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
|
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
|
EP3313402B1
(de)
|
2015-06-23 |
2023-12-27 |
Neurocrine Biosciences, Inc. |
Vmat2-inhibitoren zur behandlung von neurologischen krankheiten oder störungen
|
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
|
MX2018000216A
(es)
|
2015-07-02 |
2018-05-22 |
Celgene Corp |
Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos.
|
|
RU2018107227A
(ru)
|
2015-07-28 |
2019-08-28 |
Виоме Терапьютикс Лимитед |
Терапевтические и профилактические антибактериальные средства
|
|
US10383831B2
(en)
|
2015-08-03 |
2019-08-20 |
Temple University—Of the Commonwealth System of Higher Education |
2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
|
|
RS59158B9
(sr)
|
2015-08-17 |
2020-09-30 |
Kura Oncology Inc |
Postupci lečenja pacijenata obolelih od kancera pomoću inhibitora farneziltransferaze
|
|
EP3341392A4
(de)
|
2015-08-27 |
2019-01-23 |
President and Fellows of Harvard College |
Zusammensetzungen und verfahren zur schmerzbehandlung
|
|
EP3347486A4
(de)
|
2015-09-09 |
2019-06-19 |
The Trustees of Columbia University in the City of New York |
Reduktion von er-mam-lokalisierten app-c99 und verfahren zur behandlung der alzheimer-krankheit
|
|
US10702586B2
(en)
|
2015-09-28 |
2020-07-07 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
|
|
WO2017059385A1
(en)
|
2015-09-30 |
2017-04-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
AU2016331076B2
(en)
|
2015-10-01 |
2020-12-03 |
Nighthawk Biosciences, Inc. |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017064657A1
(en)
|
2015-10-16 |
2017-04-20 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
|
SI3875459T1
(sl)
|
2015-10-30 |
2024-06-28 |
Neurocrine Biosciences, Inc., |
Valbenazin dihidrokloridne soli in njihovi polimorfi
|
|
US20170119680A1
(en)
|
2015-10-30 |
2017-05-04 |
R.P. Scherer Technologies, Llc |
Extended release film-coated capsules
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
EP3373916A1
(de)
|
2015-11-11 |
2018-09-19 |
Celgene Corporation |
Orale retard-darreichungsformen von schwer löslichen arzneimitteln und verwendungen davon
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
RS63170B1
(sr)
|
2015-12-23 |
2022-05-31 |
Neurocrine Biosciences Inc |
Sintetički postupak za pripremanje (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1,-a]izohinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
|
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
WO2017117478A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
CA3010794A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
WO2017120446A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
|
ES2832475T3
(es)
|
2016-01-08 |
2021-06-10 |
Celgene Corp |
Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
|
|
EP3998281A1
(de)
|
2016-02-05 |
2022-05-18 |
Orionis Biosciences BV |
Cd8-bindemittel
|
|
WO2017152130A1
(en)
|
2016-03-04 |
2017-09-08 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
|
WO2017153402A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
CN109476635B
(zh)
|
2016-04-29 |
2021-07-13 |
Fgh生物科技公司 |
用于治疗疾病的二取代吡唑类化合物
|
|
WO2017192858A1
(en)
|
2016-05-04 |
2017-11-09 |
Purdue Pharma L.P. |
Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
|
|
EP3454887B1
(de)
|
2016-05-13 |
2021-01-20 |
Orionis Biosciences BV |
Zielgerichtete mutanten-interferon-beta und verwendungen davon
|
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN109562108A
(zh)
|
2016-07-18 |
2019-04-02 |
法米娜生物技术公司 |
用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺
|
|
JOP20190008A1
(ar)
|
2016-07-26 |
2019-01-24 |
Purdue Pharma Lp |
علاج ومنع اضطرابات النوم
|
|
JP2019523279A
(ja)
|
2016-07-29 |
2019-08-22 |
サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
化合物および組成物ならびにそれらの使用
|
|
MA45857A
(fr)
|
2016-07-29 |
2021-05-19 |
Sunovion Pharmaceuticals Inc |
Composés et compositions, et utilisations associées
|
|
MX2019002607A
(es)
|
2016-09-07 |
2019-09-18 |
Univ Temple |
Composiciones y metodos para el tratamiento de resistencia a la insulina.
|
|
US11339142B2
(en)
|
2016-09-07 |
2022-05-24 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
|
MA46285A
(fr)
|
2016-09-19 |
2019-07-31 |
Mei Pharma Inc |
Polythérapie
|
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2018069312A1
(en)
|
2016-10-11 |
2018-04-19 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Treatment of synucleinopathies
|
|
US11154591B2
(en)
|
2016-10-14 |
2021-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
|
EP3528805B1
(de)
|
2016-10-21 |
2023-12-06 |
Cedars-Sinai Medical Center |
Simvastatin und chemotherapeutische konjugate mit einem heptamethincarbocyaninfarbstoff zur resensibilisierung von menschlichen tumoren gegen hormonale antagonisten und chemotherapie
|
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
|
TW201818965A
(zh)
|
2016-11-03 |
2018-06-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
|
|
CN116987014A
(zh)
|
2016-11-09 |
2023-11-03 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
WO2018102455A1
(en)
|
2016-12-01 |
2018-06-07 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
|
EP4400171A2
(de)
|
2016-12-02 |
2024-07-17 |
Neurocrine Biosciences, Inc. |
Verwendung von valbenazin zur behandlung von schizophrenie oder schizoaffektiver störung
|
|
EP3573979A1
(de)
|
2017-01-27 |
2019-12-04 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino)-methyl)benzyl)oxy)isoindolin-2-yl)piperidin-2,6-dion und isotopologe davon
|
|
US20190381016A1
(en)
|
2017-01-27 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
CN110546160A
(zh)
|
2017-02-06 |
2019-12-06 |
奥里尼斯生物科学公司 |
靶向嵌合蛋白及其用途
|
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
US10889587B2
(en)
|
2017-02-06 |
2021-01-12 |
Spero Therapeutics, Inc. |
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
|
|
CA3050601A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzm |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
CA3053903A1
(en)
|
2017-02-16 |
2018-08-23 |
Sunovion Pharmaceuticals Inc. |
Methods of treating schizophrenia
|
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
KR102138904B1
(ko)
|
2017-02-21 |
2020-07-28 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
|
|
WO2018157163A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Vsig8-based chimeric proteins
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
WO2018165142A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
|
CA3050086A1
(en)
|
2017-03-26 |
2018-10-04 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
|
BR112019017962A2
(pt)
|
2017-03-27 |
2020-05-19 |
Univ California |
método para inibição de crescimento, de migração, de proliferação e/ou de metástase de uma célula pré-cancerosa, cancerosa ou neoplásica ou de inibição de um patógeno, composição probiótica tópica, bandagem ou curativo, método de tratamento de dano na pele devido à radiação uv, e, composição farmacêutica
|
|
CN110914276A
(zh)
|
2017-03-29 |
2020-03-24 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
|
KR20200012833A
(ko)
|
2017-03-29 |
2020-02-05 |
사이트원 테라퓨틱스, 인코포레이티드 |
통증 치료용 11,13-개질된 색시톡신
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
EP3624796A1
(de)
|
2017-05-19 |
2020-03-25 |
NFlection Therapeutics, Inc. |
Pyrrolopyridinanilinverbindungen zur behandlung von hauterkrankungen
|
|
ES2913213T3
(es)
|
2017-05-19 |
2022-06-01 |
Nflection Therapeutics Inc |
Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
|
|
EP3630079A4
(de)
|
2017-05-31 |
2021-02-24 |
The Children's Medical Center Corporation |
Targeting von lysin-demethylasen (kdm) als therapeutische strategie für diffuses grosses b-zell-lymphom
|
|
BR112019025420A2
(pt)
|
2017-06-01 |
2020-06-16 |
Xoc Pharmaceuticals, Inc. |
Compostos policíclicos e usos destes
|
|
US11400136B2
(en)
|
2017-06-19 |
2022-08-02 |
President And Fellows Of Harvard College |
Methods and compositions for treating a microbial infection
|
|
WO2019005874A1
(en)
|
2017-06-26 |
2019-01-03 |
The Trustees Of Columbia University In The City Of New York |
CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
|
|
EP3652318A1
(de)
|
2017-07-11 |
2020-05-20 |
Actym Therapeutics, Inc. |
Manipulierte immunstimulierende bakterienstämme und verwendungen davon
|
|
US11517557B2
(en)
|
2017-07-13 |
2022-12-06 |
Tonix Pharmaceuticals Holding Corp. |
Analogs of cyclobenzaprine and amitriptyline
|
|
EP3654960A1
(de)
|
2017-07-16 |
2020-05-27 |
Neuere, LLC |
Ambroxol zur verbesserung und/oder verlängerung der gesundheit, lebensdauer und/oder geistigen klarheit
|
|
CA3070993A1
(en)
|
2017-08-02 |
2019-02-07 |
Sunovion Pharmaceuticals Inc. |
Isochroman compounds and uses thereof
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP3664804A4
(de)
|
2017-08-07 |
2021-04-14 |
Kura Oncology, Inc. |
Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
|
|
EP3684333A2
(de)
|
2017-09-21 |
2020-07-29 |
Neurocrine Biosciences, Inc. |
Hochdosierte valbenazinformulierung und zusammensetzungen, verfahren und kits dazu
|
|
AU2018346500A1
(en)
|
2017-10-04 |
2020-04-02 |
The Regents Of The University Of California |
Immunomodulatory oligosaccharides
|
|
WO2019074492A1
(en)
|
2017-10-10 |
2019-04-18 |
Obrien Christopher F |
METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
|
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
EP3713916A1
(de)
|
2017-11-20 |
2020-09-30 |
Kiakos, Konstantinos |
Aus 3,5-diarylidenyl-n-substituiertes-piperid-4-on abgeleitete inhibitoren der stat3-weg-aktivität und verwendungen davon
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
AU2018383098A1
(en)
|
2017-12-11 |
2020-05-28 |
Tonix Pharma Holdings Limited |
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
|
|
WO2019118984A2
(en)
|
2017-12-15 |
2019-06-20 |
Solarea Bio, Inc. |
Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
|
|
WO2019126136A2
(en)
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
|
US20190210973A1
(en)
|
2018-01-05 |
2019-07-11 |
The Curators Of The University Of Missouri |
Compounds and methods for treatment of cystic fibrosis
|
|
TW202406538A
(zh)
|
2018-01-10 |
2024-02-16 |
美商克拉治療有限責任公司 |
包含苯基磺醯胺之醫藥組合物及其治療應用
|
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
EP3743049A1
(de)
|
2018-01-24 |
2020-12-02 |
Purdue Pharma LP |
Behandlung und prävention von schlafstörungen
|
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
KR20200141986A
(ko)
|
2018-02-12 |
2020-12-21 |
다이어비티스-프리, 인크. |
개선된 길항성 항-인간 cd40 단클론 항체
|
|
JP2021513972A
(ja)
|
2018-02-16 |
2021-06-03 |
サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
社会的機能障害の治療方法
|
|
TW202000205A
(zh)
|
2018-02-21 |
2020-01-01 |
美商Ａｉ治療公司 |
使用阿吡莫德與麩胺酸性劑的組合治療
|
|
CA3094391A1
(en)
|
2018-03-22 |
2019-09-26 |
The Children's Medical Center Corporation |
Methods and compositions relating to lung repair
|
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
EP3814327A1
(de)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorphenoxy)pentansäure-derivate und verwandte verbindungen als caspase-inhibitoren zur behandlung kardiovaskulärer erkrankungen
|
|
BR112021000315A2
(pt)
|
2018-07-11 |
2021-08-03 |
Actym Therapeutics, Inc. |
cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos
|
|
JP2021528481A
(ja)
|
2018-08-15 |
2021-10-21 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２阻害剤を投与するための方法
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
CN112771067A
(zh)
|
2018-08-29 |
2021-05-07 |
沙塔克实验室有限公司 |
包含基于SIRPα的嵌合蛋白的组合疗法
|
|
WO2020051379A1
(en)
|
2018-09-05 |
2020-03-12 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases
|
|
US11980647B2
(en)
|
2018-09-05 |
2024-05-14 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
|
WO2020072835A1
(en)
|
2018-10-03 |
2020-04-09 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
AU2019372141A1
(en)
|
2018-11-01 |
2021-05-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
|
CA3120371A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
US20220144819A1
(en)
|
2018-11-20 |
2022-05-12 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
MA55143A
(fr)
|
2018-11-20 |
2021-09-29 |
H Lee Moffitt Cancer Center & Res Institute Inc |
Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
|
|
EP3883554A4
(de)
|
2018-11-20 |
2022-11-23 |
NFlection Therapeutics, Inc. |
Aryl-anilin- und heteroaryl-anilinverbindungen zur behandlung von muttermalen
|
|
US20230078755A1
(en)
|
2018-12-19 |
2023-03-16 |
Shy Therapeutics, Llc |
Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
|
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
|
KR20210106513A
(ko)
|
2018-12-21 |
2021-08-30 |
쿠라 온콜로지, 인크. |
편평 세포 암종을 위한 요법
|
|
EP3921038A1
(de)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
WO2020176809A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CA3132613A1
(en)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Caspase inhibitors and methods of use thereof
|
|
JP2022525169A
(ja)
|
2019-03-14 |
2022-05-11 |
サノビオン ファーマシューティカルズ インク |
イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
|
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
|
EP3941900A1
(de)
|
2019-03-22 |
2022-01-26 |
Deutsches Krebsforschungszentrum |
Neuartige inhibitoren der histon-deacetylase 10
|
|
EP3712127A1
(de)
|
2019-03-22 |
2020-09-23 |
Deutsches Krebsforschungszentrum |
Neuartige inhibitoren der histon-deacetylase 10
|
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
|
JP2022527825A
(ja)
|
2019-04-03 |
2022-06-06 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
WO2020227437A1
(en)
*
|
2019-05-06 |
2020-11-12 |
Axial Biotherapeutics, Inc. |
Sustained release solid dosage forms for modulating the colonic microbiome
|
|
WO2020246503A1
(ja)
|
2019-06-03 |
2020-12-10 |
株式会社大分大学先端医学研究所 |
狂犬病治療のための環状アミド化合物およびその方法
|
|
CA3143713A1
(en)
|
2019-06-19 |
2020-12-24 |
Solarea Bio, Inc. |
Microbial compositions and methods for producing upgraded probiotic assemblages
|
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
|
TW202118750A
(zh)
|
2019-07-26 |
2021-05-16 |
美商艾斯佩維他治療學公司 |
官能化的長鏈烴一元及二元羧酸及其用於預防或治療疾病的用途
|
|
US10792262B1
(en)
|
2019-07-29 |
2020-10-06 |
Saol International Limited |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
|
US11654124B2
(en)
|
2019-07-29 |
2023-05-23 |
Amneal Pharmaceuticals Llc |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
JP2022545917A
(ja)
|
2019-08-27 |
2022-11-01 |
トニックス ファーマ リミテッド |
修飾ｔｆｆ２ポリペプチド
|
|
MX2022003166A
(es)
|
2019-09-16 |
2022-06-29 |
Dice Alpha Inc |
Moduladores de il-17a y usos de los mismos.
|
|
EP4034236A1
(de)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Verbindungen zur behandlung von lebererkrankungen
|
|
AU2020359526A1
(en)
|
2019-10-01 |
2022-04-21 |
Molecular Skin Therapeutics, Inc. |
Benzoxazinone compounds as KLK5/7 dual inhibitors
|
|
CA3177479A1
(en)
|
2019-11-12 |
2021-05-20 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
|
JP2023503899A
(ja)
|
2019-11-22 |
2023-02-01 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
|
AU2020396866A1
(en)
|
2019-12-02 |
2022-06-23 |
Celgene Corporation |
Therapy for the treatment of cancer
|
|
US20230093147A1
(en)
|
2020-03-09 |
2023-03-23 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
|
TW202206062A
(zh)
|
2020-04-24 |
2022-02-16 |
美國坦普大學 高等教育聯邦系統 |
治療非酒精性脂肪肝炎的方法
|
|
US20230102247A1
(en)
|
2020-04-28 |
2023-03-30 |
President And Fellows Of Harvard College |
Methods and compositions relating to ionic liquid adjuvants
|
|
WO2021226033A1
(en)
|
2020-05-07 |
2021-11-11 |
President And Fellows Of Harvard College |
Hyaluronic acid drug conjugates
|
|
EP4157923A2
(de)
|
2020-05-29 |
2023-04-05 |
President And Fellows Of Harvard College |
Mit polyphenolfunktionalisierten biologisch aktiven nanokomplexen manipulierte lebende zellen
|
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
US20230102840A1
(en)
|
2020-06-23 |
2023-03-30 |
President And Fellows Of Harvard College |
Compositions and methods relating to combinatorial hyaluronic acid conjugates
|
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
|
JP2023532312A
(ja)
|
2020-06-30 |
2023-07-27 |
プロセッタ バイオサイエンシズ， インク． |
イソキノリン誘導体、合成の方法及びそれらの使用
|
|
US20230241171A1
(en)
|
2020-07-10 |
2023-08-03 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
|
CA3191433A1
(en)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
|
MX2023001741A
(es)
|
2020-08-14 |
2023-04-25 |
Siteone Therapeutics Inc |
Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022090482A1
(en)
|
2020-10-30 |
2022-05-05 |
Ds Biopharma Limited |
Pharmaceutical compositions comprising 15-hetre and methods of use thereof
|
|
US20240117033A1
(en)
|
2021-01-15 |
2024-04-11 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
|
EP4284394A1
(de)
|
2021-01-26 |
2023-12-06 |
Cytocares (Shanghai) Inc. |
Chimäre antigenrezeptor(car)-konstrukte und nk-zellen zur expression von car-konstrukten
|
|
EP4284377A1
(de)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Verfahren zur behandlung von fibrotischen erkrankungen
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
WO2022187573A1
(en)
|
2021-03-05 |
2022-09-09 |
President And Fellows Of Harvard College |
Methods and compositions relating to cell membrane hybridization and camouflaging
|
|
WO2022189010A1
(en)
|
2021-03-07 |
2022-09-15 |
Givaudan Sa |
Methods and compositions for treating and preventing urinary tract infections
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
CA3211505A1
(en)
|
2021-03-10 |
2022-09-15 |
Lalit Kumar Sharma |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
|
IL305676A
(en)
|
2021-03-19 |
2023-11-01 |
Tiba Biotech Llc |
Expression systems of artificial RNA replicon derived from alphavirus
|
|
EP4326721A1
(de)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclische imidazolidinone und imidazolidindione zur behandlung von leichtkettiger amyloidose
|
|
EP4347568A1
(de)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryldiamid-ire1/xbp1s-aktivatoren
|
|
WO2022265880A1
(en)
|
2021-06-16 |
2022-12-22 |
President And Fellows Of Harvard College |
Improved methods and compositions for drug delivery relating to ionic liquids
|
|
WO2022271537A1
(en)
|
2021-06-25 |
2022-12-29 |
President And Fellows Of Harvard College |
Compositions and methods relating to injectable microemulsions
|
|
KR20240044458A
(ko)
|
2021-08-05 |
2024-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
|
|
WO2023034507A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
|
|
WO2023034508A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for promoting adipocyte beiging
|
|
WO2023034504A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
|
|
US20230144855A1
(en)
|
2021-09-01 |
2023-05-11 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin
|
|
EP4399276A2
(de)
|
2021-09-09 |
2024-07-17 |
Flagship Pioneering Innovations VI, LLC |
Verfahren und zusammensetzungen zur modulation von kublet-zellen und für mukoobstruktive erkrankungen
|
|
WO2023039162A1
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating enteroendocrine cells
|
|
EP4402281A2
(de)
|
2021-09-14 |
2024-07-24 |
Flagship Pioneering Innovations VI, LLC |
Verfahren und zusammensetzungen zur störung von monozyten und neutrophillinien
|
|
WO2023055457A1
(en)
|
2021-09-29 |
2023-04-06 |
Amneal Pharmaceuticals Llc |
Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
|
|
WO2023059846A1
(en)
|
2021-10-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
EP4162933A1
(de)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Verbindung zur behandlung von nicht-alkoholischer fettlebererkrankung und verwandten erkrankungen
|
|
AU2022368836A1
(en)
|
2021-10-22 |
2024-05-02 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
WO2023076997A1
(en)
|
2021-10-28 |
2023-05-04 |
Zywie, Llc |
Modified forms of ambroxol for therapeutic use
|
|
AU2022391767A1
(en)
|
2021-11-22 |
2024-07-04 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
|
AU2022399572A1
(en)
|
2021-11-30 |
2024-05-02 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
|
US20230303580A1
(en)
|
2022-03-28 |
2023-09-28 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
|
US20230348909A1
(en)
|
2022-03-30 |
2023-11-02 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
TW202406901A
(zh)
|
2022-04-14 |
2024-02-16 |
美商必治妥美雅史谷比公司 |
新穎gspt1化合物以及新穎化合物之使用方法
|
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
|
WO2023230524A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of secretory and/or catalytic cells and methods using the same
|
|
US20240158370A1
(en)
|
2022-09-09 |
2024-05-16 |
Innovo Therapeutics, Inc. |
CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
|
|
US20240131005A1
(en)
|
2022-09-30 |
2024-04-25 |
Boulder Bioscience Llc |
Compositions and methods for treating non-hemorrhagic closed head injury
|
|
WO2024086246A2
(en)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
|
|
WO2024091863A1
(en)
|
2022-10-25 |
2024-05-02 |
Starrock Pharma Llc |
Combinatorial, and rotational combinatorial therapies for obesity and other diseases
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
WO2024097940A1
(en)
|
2022-11-04 |
2024-05-10 |
Bristol-Myers Squibb Company |
Therapy for the treatment of cancer
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2024145662A1
(en)
|
2022-12-30 |
2024-07-04 |
Altay Therapeutics, Inc. |
2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
|